Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Combination approach slows osteosarcoma growth and prolongs survival in preclinical models (opens in a new tab)

news-medical.net · 2026-10-20

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 2 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of six claims overstate the study. Two of six check out. Two claims the study doesn't address.

  • 2 supported
  • 2 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedPublished in the Journal of Experimental Medicine, a combination approach slowed tumor growth and prolonged survival in preclinical models of osteosarcoma.View evidenceHide evidence

Why this verdict

The abstract supports preclinical growth suppression from AKT inhibition plus EP300 degradation, including in orthotopic xenografts. However, the supplied profile does not report prolonged survival, and the xenograft unit explicitly notes that it is unclear whether survival was assessed. The headline-style claim therefore goes beyond the abstract evidence by adding survival benefit.

1

Study evidence

Combining AKT inhibition with EP300 degradation (JQAD1) synergistically suppressed growth of AKT-dysregulated osteosarcoma cells in vitro (reported in the abstract).

“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro ...”
2

Study evidence

Combining AKT inhibition with the EP300 degrader JQAD1 synergistically suppressed the growth of AKT-dysregulated osteosarcoma cells in orthotopic xenograft models (abstract statement).

“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells ... in orthotopic xenografts.”
Claim 2 of 6OverstatedThe paired drugs had a synergistic effect in mouse model xenografts of patient tumors, slowing tumor growth and increasing survival.View evidenceHide evidence

Why this verdict

The abstract supports synergistic suppression of tumor growth in orthotopic osteosarcoma xenografts. It does not establish that the xenografts were patient-derived tumors, and it does not report increased survival; the profile notes survival endpoints are unclear at abstract depth. The growth-suppression component is supported, but the patient-tumor and survival additions overstate the supplied evidence.

1

Study evidence

Combining AKT inhibition with the EP300 degrader JQAD1 synergistically suppressed the growth of AKT-dysregulated osteosarcoma cells in orthotopic xenograft models (abstract statement).

“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells ... in orthotopic xenografts.”
Claim 3 of 6Not coveredMost osteosarcoma samples responsive to EP300 degradation had mutations that hyperactivated the AKT pathway, suggesting a possible biomarker for sensitivity to the combination approach.View evidenceHide evidence

Why this verdict

The abstract supports an association between PI3K–AKT–mTOR pathway dysregulation and sensitivity to EP300 loss, consistent with a possible biomarker concept. But at abstract depth it does not specify that most responsive osteosarcoma samples had mutations, which mutations were involved, or the proportion of responsive samples. Those details may require full-text evidence.

1

Study evidence

A genetically defined osteosarcoma subgroup with PI3K–AKT–mTOR dysregulation is selectively sensitive to EP300 loss as shown by chemical degradation with the selective EP300 degrader JQAD1 and by genetic perturbation.

“Using a selective EP300 degrader (JQAD1), we identify that a genetically defined subgroup of OS with dysregulation of the PI3K-AKT-mTOR pathway is genetically and chemically sensitive to loss of EP300.”
Claim 4 of 6Not coveredResistant osteosarcomas seemed able to 'outrun' EP300 degradation by making more proteins overall, while sensitive cancers had a slower rate of global protein production.View evidenceHide evidence

Why this verdict

The supplied abstract-level profile reports that EP300-degrader/AKT-inhibitor synergy across more than 850 cancer cell lines is predicted by elevated protein synthetic rates. It does not describe resistant osteosarcomas 'outrunning' EP300 degradation through higher overall protein production, nor does it establish that sensitive cancers have slower global protein production. This mechanistic wording is not verifiable from the abstract profile.

1

Study evidence

In a pan-cancer analysis of over 850 cell lines, predicted synergy between an EP300-selective degrader and AKT inhibition is associated with and can be predicted by elevated protein synthetic rates.

“These observations extend across >850 cancer cell lines, where synergy is predicted by elevated protein synthetic rates.”
Claim 5 of 6SupportedScientists co-led by St. Jude Children's Research Hospital identified a potential therapeutic vulnerability in some forms of osteosarcoma.View evidenceHide evidence

Why this verdict

The abstract supports the scientific core: a genetically defined osteosarcoma subgroup with PI3K–AKT–mTOR dysregulation is sensitive to EP300 loss, and co-targeting EP300 and AKT is supported in preclinical models. The supplied paper profile does not independently verify the St. Jude co-leadership detail, but the therapeutic-vulnerability framing is appropriately hedged as potential and limited to some osteosarcomas.

1

Study evidence

A genetically defined osteosarcoma subgroup with PI3K–AKT–mTOR dysregulation is selectively sensitive to EP300 loss as shown by chemical degradation with the selective EP300 degrader JQAD1 and by genetic perturbation.

“Using a selective EP300 degrader (JQAD1), we identify that a genetically defined subgroup of OS with dysregulation of the PI3K-AKT-mTOR pathway is genetically and chemically sensitive to loss of EP300.”
2

Study evidence

Combining AKT inhibition with EP300 degradation (JQAD1) synergistically suppressed growth of AKT-dysregulated osteosarcoma cells in vitro (reported in the abstract).

“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro ...”
Claim 6 of 6SupportedThe therapies degraded EP300 and inhibited AKT, highlighting the combination's clinical potential.View evidenceHide evidence

Why this verdict

The abstract supports the combination of an EP300 degrader, JQAD1, with AKT inhibition and reports synergistic growth suppression in AKT-dysregulated osteosarcoma cells and orthotopic xenografts. Framing this as clinical potential is acceptable only because it is hedged and the story caveats identify the work as preclinical rather than established patient therapy.

1

Study evidence

Combining AKT inhibition with EP300 degradation (JQAD1) synergistically suppressed growth of AKT-dysregulated osteosarcoma cells in vitro (reported in the abstract).

“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro ...”
2

Study evidence

Combining AKT inhibition with the EP300 degrader JQAD1 synergistically suppressed the growth of AKT-dysregulated osteosarcoma cells in orthotopic xenograft models (abstract statement).

“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells ... in orthotopic xenografts.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Cancer-wide integrative chemical-genetic analysis found greater dependency on EP300 than CBP across many cancer lineages, including osteosarcoma.

    The story focuses on osteosarcoma therapeutic vulnerability and combination treatment, but does not reflect the broader pan-cancer EP300-versus-CBP dependency analysis.

    From secondary_data integrative chemical-genetic analysis

  • Activated AKT is reported to promote EP300-degrader sensitivity through relocalization of EP300, CBP, and H3K27ac to subtype-enriched dependency loci.

    The story does not cover the chromatin-relocalization mechanism described in the abstract profile.

    From chromatin profiling and AKT perturbation (per appraisal unit scope)

  • Across more than 850 cancer cell lines, predicted EP300-degrader/AKT-inhibitor synergy is associated with and predicted by elevated protein synthetic rates.

    The story mentions global protein production in a resistance/sensitivity framing, but does not accurately reflect the abstract-level pan-cancer finding that elevated protein synthetic rates predict combination synergy.

    From secondary_data

  • The abstract profile provides no quantitative effect sizes, sample sizes, statistical details, animal numbers, dosing regimens, or randomization/blinding information for the in vivo work.

    The story caveats preclinical status but do not mention the abstract-level absence of quantitative and risk-of-bias details for xenograft experiments, which limits confidence in the magnitude and robustness of the reported in vivo effect.

    From Orthotopic xenograft, in vivo drug treatment

5 things the story did carry across
  • A genetically defined osteosarcoma subgroup with PI3K–AKT–mTOR dysregulation is selectively sensitive to EP300 loss using the selective EP300 degrader JQAD1.
  • Combining AKT inhibition with EP300 degradation synergistically suppresses growth of AKT-dysregulated osteosarcoma cells in vitro.
  • Combining AKT inhibition with EP300 degradation synergistically suppresses growth in orthotopic osteosarcoma xenografts.
  • The evidence is preclinical, based on cell-line analyses and animal xenografts rather than proven patient treatment.
  • The findings apply to a genetically defined, AKT/PI3K–mTOR-dysregulated subset of osteosarcoma rather than all osteosarcoma.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroA genetically defined osteosarcoma subgroup with dysregulated PI3K–AKT–mTOR signaling is selectively sensitive to EP300 loss (using the selective EP300 degrader JQAD1), and activated AKT promotes this sensitivity via relocalization of EP300/CBP/H3K27ac to dependency loci.in vitro degrader and genetic perturbation assaysExpand

In plain English

In osteosarcoma models, a genetically defined subgroup with dysregulated PI3K–AKT–mTOR signaling shows selective sensitivity to loss of EP300, demonstrated chemically using the selective EP300 degrader JQAD1 and via genetic perturbation. Activated AKT drives this sensitivity and is associated with relocalization of EP300, CBP, and H3K27ac to subtype-enriched dependency loci.

Key findings

  • A genetically defined osteosarcoma subgroup with PI3K–AKT–mTOR dysregulation is selectively sensitive to EP300 loss as shown by chemical degradation with the selective EP300 degrader JQAD1 and by genetic perturbation.
  • Activated AKT enhances sensitivity to EP300 degradation, accompanied by relocalization of EP300, CBP, and H3K27ac to dependency-associated genomic loci.
“Using a selective EP300 degrader (JQAD1), we identify that a genetically defined subgroup of OS with dysregulation of the PI3K-AKT-mTOR pathway is genetically and chemically sensitive to loss of EP300.”
What this piece can’t prove
  • Findings described for cell-line models may not directly translate to clinical tumor biology without additional validation.

3 further details could not be confirmed from the summary.

2secondary dataA cancer-wide integrative chemical-genetic analysis shows many cancer lineages (including osteosarcoma) have greater functional dependency on EP300 than on its paralog CBP.secondary data integrative chemical-genetic analysisExpand

In plain English

The authors conducted a cancer-wide integrative chemical-genetic analysis of cancer cell lines and report a greater functional dependency on EP300 than on its paralog CBP across cell lines from most cancer lineages, with osteosarcoma highlighted among the sensitive lineages.

Key findings

  • A cancer-wide integrative chemical-genetic analysis shows enhanced dependency on EP300 versus CBP across cell lines from most cancer lineages, including osteosarcoma.qualitative: enhanced dependency on EP300 compared with CBP
“Using a cancer-wide integrative chemical-genetic analysis, we demonstrate enhanced dependency on EP300, compared with CBP, in cell lines from most cancer lineages, including lethal osteosarcoma (OS).”
What this piece can’t prove
  • Findings are based on integrative analyses of cancer cell lines; applicability to tumors in patients is not established here.
  • Abstract provides no methodological detail (e.g., data sources, sample counts, statistical controls) limiting assessment of potential biases or confounders.

1 further detail could not be confirmed from the summary.

3in vitroA genetically defined osteosarcoma subgroup with dysregulated PI3K–AKT–mTOR signaling is selectively sensitive to EP300 loss (using the selective EP300 degrader JQAD1), and activated AKT promotes this sensitivity via relocalization of EP300/CBP/H3K27ac to dependency loci.chromatin profiling and AKT perturbation (per appraisal unit scope)Expand

In plain English

The abstract reports that a genetically defined osteosarcoma subgroup with dysregulated PI3K–AKT–mTOR signaling is selectively sensitive to EP300 loss using the selective EP300 degrader JQAD1. Activated AKT is described to promote this sensitivity through relocalization of EP300, CBP, and H3K27ac to genetic subtype–enriched dependency loci.

Key findings

  • A genetically defined osteosarcoma subgroup with dysregulated PI3K–AKT–mTOR signaling is selectively sensitive to EP300 loss using the selective EP300 degrader JQAD1; activated AKT promotes this sensitivity via relocalization of EP300, CBP, and H3K27ac to genetic subtype–enriched dependency loci.
“Activated AKT promotes sensitivity to JQAD1, driven by relocalization of EP300, CBP and H3K27ac to genetic subtype-enriched dependency loci.”
What this piece can’t prove
  • The abstract does not specify which chromatin-profiling method was used (e.g., ChIP-seq, CUT&RUN, CUT&Tag) or technical validation (antibody validation, controls).

3 further details could not be confirmed from the summary.

4in vitroCombining AKT inhibition with EP300 degradation (JQAD1) synergistically suppresses growth of AKT-dysregulated osteosarcoma cells in vitro and in orthotopic xenografts.in vitro drug combination assayExpand

In plain English

The paper reports that combining AKT inhibition with selective EP300 degradation (JQAD1) produces a synergistic suppression of growth in osteosarcoma cell lines with dysregulated AKT signaling, based on in vitro combination experiments described in the abstract.

Key findings

  • Combining AKT inhibition with EP300 degradation (JQAD1) synergistically suppressed growth of AKT-dysregulated osteosarcoma cells in vitro (reported in the abstract).
“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro ...”
What this piece can’t prove
  • Information is limited to the abstract; detailed experimental parameters (AKT inhibitor identity and doses, JQAD1 dosing, cell line identities and numbers, assay types, and statistical metrics) are not provided.

2 further details could not be confirmed from the summary.

5in vivo animalCombining AKT inhibition with EP300 degradation (JQAD1) synergistically suppresses growth of AKT-dysregulated osteosarcoma cells in vitro and in orthotopic xenografts.Orthotopic xenograft, in vivo drug treatmentExpand

In plain English

The paper reports that, in orthotopic osteosarcoma xenograft models of AKT-dysregulated tumors, combining AKT inhibition with the EP300 degrader JQAD1 synergistically suppressed tumor growth (abstract statement).

Key findings

  • Combining AKT inhibition with the EP300 degrader JQAD1 synergistically suppressed the growth of AKT-dysregulated osteosarcoma cells in orthotopic xenograft models (abstract statement).
“AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells ... in orthotopic xenografts.”
What this piece can’t prove

5 further details could not be confirmed from the summary.

6secondary dataAcross >850 cancer cell lines, EP300-degrader/AKT-inhibitor synergy is predictable and is associated with (and predicted by) elevated protein synthetic rates.secondary dataExpand

In plain English

The authors report that, in a pan-cancer analysis encompassing more than 850 cancer cell lines, predicted synergy between an EP300-selective degrader and AKT inhibition is associated with — and can be predicted by — elevated protein synthetic rates.

Key findings

  • In a pan-cancer analysis of over 850 cell lines, predicted synergy between an EP300-selective degrader and AKT inhibition is associated with and can be predicted by elevated protein synthetic rates.
“These observations extend across >850 cancer cell lines, where synergy is predicted by elevated protein synthetic rates.”
What this piece can’t prove
  • Unclear whether synergy was experimentally measured across many lines or inferred by computational prediction from existing data.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

And 9 more candidates considered.